Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 31st total of 1,420,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.3% of the company’s shares are short sold.
Athira Pharma Price Performance
NASDAQ:ATHA traded up $0.01 during mid-day trading on Thursday, reaching $0.53. The company’s stock had a trading volume of 463,920 shares, compared to its average volume of 211,201. Athira Pharma has a twelve month low of $0.41 and a twelve month high of $4.30. The company’s fifty day simple moving average is $0.58 and its two-hundred day simple moving average is $1.23. The stock has a market cap of $20.65 million, a P/E ratio of -0.19 and a beta of 2.99.
Athira Pharma (NASDAQ:ATHA – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. Sell-side analysts expect that Athira Pharma will post -2.35 EPS for the current fiscal year.
Hedge Funds Weigh In On Athira Pharma
About Athira Pharma
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.
Recommended Stories
- Five stocks we like better than Athira Pharma
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Stock Market Upgrades: What Are They?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.